INmune Bio's XPro1595 Shows Statistically Significant White Matter Treatment Effect in Alzheimer's Trial
Event summary
- INmune Bio's XPro1595 demonstrated a statistically significant treatment effect on white matter in the Phase 2 MINDFuL Alzheimer's trial (p=0.0028, Cohen's d=0.46, n=200).
- The effect was stronger in biomarker-enriched patients with elevated inflammation (p=0.0098, Cohen's d=0.59, n=100).
- The company secured FDA Fast Track designation and End-of-Phase 2 alignment for its Phase 2b/3 registrational program.
- INmune Bio plans to present the complete dataset at AAIC 2026 in July.
The big picture
INmune Bio's results highlight the growing recognition of white matter degeneration as a critical factor in Alzheimer's progression, shifting focus from traditional gray matter targets. The company's precision-medicine approach, validated by these findings, positions it favorably in the competitive landscape of neurodegenerative disease treatments. The strategic alignment with regulatory bodies further de-risks the path to market for XPro1595.
What we're watching
- Regulatory Pathway
- Whether the FDA's alignment on the Phase 2b/3 registrational program will accelerate approval timelines for XPro1595.
- Clinical Validation
- The impact of the chi-separation MRI biomarker results on the broader acceptance of XPro1595's mechanism in neuroinflammation.
- Pipeline Expansion
- The pace at which INmune Bio can leverage these results to explore XPro1595's potential in other neuroinflammatory diseases.
Related topics